thymidylate synthase
"
Raltitrexed (112887-68-0)
Raltitrexed (112887-68-0) Raltitrexed is an anti-tumor pharmaceutical agent specifically developed for the treatment of advanced colorectal cancer. As a highly selective inhibitor of thymidylate synthase (TS), it targets the key enzyme responsible for the biochemical conversion of dUMP to dTMP. The compound enters cells via the reduced folate/methotrexate cell membrane carrier and is converted to polyglutamate species by folylpolyglutamate synthase within 4 hours, where it
5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thiophenecarboxylic acid (131052-68-1)
5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thiophenecarboxylic acid (131052-68-1) 5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thiophenecarboxylic acid is used as an intermediate in the synthesis of Raltitrexed. Product Specifications Product Name: 5-[N-(tert-butoxycarbonyl)-N-methylamino]-2-thiophenecarboxylic acid CAS No.: 131052-68-1 Assay: 98% End Use: Raltitrexed Molecular Formula: C11 H15 NO4 S Molecular Weight: 257.3 Shelf Life: 2 Years Package: 25kg/drum Product
6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one (112888-43-4)
6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one (112888-43-4) 6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one is a key intermediate used in the synthesis of Raltitrexed, an important pharmaceutical compound. Product Specifications Product Name: 6-Bromomethyl-3,4-dihydro-2-methyl-quinazolin-4-one CAS No.: 112888-43-4 Assay: 98% End Use: Raltitrexed Intermediate Molecular Formula: C10 H9 BrN2 O Molecular Weight: 253.1 Shelf Life: 2 Years Package: 25kg/drum Product
5-Nitrothiophene-2-carboxylicacid (6317-37-9)
5-Nitrothiophene-2-carboxylic Acid (6317-37-9) 5-Nitrothiophene-2-carboxylic Acid is a key chemical intermediate used in the synthesis of Raltitrexed, an important pharmaceutical compound. Product Name: 5-Nitrothiophene-2-carboxylic Acid CAS No.: 6317-37-9 Assay: 98% End Use: Raltitrexed Intermediate Molecular Formula: C5 H3 NO4 S Molecular Weight: 173.15 g/mol Shelf Life: 2 Years Package: 25kg/drum
Pralatrexate (146464-95-1)
Pralatrexate (52853-40-4) Pralatrexate is an injectable DHFR inhibitor approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This antineoplastic agent works by inhibiting folate enzymes DHFR and thymidylate synthase, representing a well-validated approach to cancer treatment. Product Specifications Product Name: Pralatrexate CAS No.: 52853-40-4 Assay: 98.9% Specification: CP, EP, In-house, as required Molecular Formula: C23 H23